We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock

Delisted

DCPH was delisted on the 10th of June, 2024.

140 hedge funds and large institutions have $450M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 58 increasing their positions, 32 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

434% more call options, than puts

Call options by funds: $19.1M | Put options by funds: $3.57M

81% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 32

13% less funds holding

Funds holding: 161140 (-21)

41% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 49

69% less capital invested

Capital invested by funds: $1.43B → $450M (-$982M)

75% less funds holding in top 10

Funds holding in top 10: 41 (-3)

Holders
140
Holders Change
-21
Holders Change %
-13.04%
% of All Funds
2.15%
Holding in Top 10
1
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-75%
% of All Funds
0.02%
New
29
Increased
58
Reduced
32
Closed
49
Calls
$19.1M
Puts
$3.57M
Net Calls
+$15.5M
Net Calls Change
+$401K
Name Holding Trade Value Shares
Change
Change in
Stake
Dimensional Fund Advisors
26
Dimensional Fund Advisors
Texas
$2.91M +$1.49M +79,192 +36%
Charles Schwab
27
Charles Schwab
California
$2.88M +$163K +8,670 +3%
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$2.74M +$3.94M +209,362 +295%
Jacobs Levy Equity Management
29
Jacobs Levy Equity Management
New Jersey
$2.46M +$4.35M +231,382 +1,121%
Assenagon Asset Management
30
Assenagon Asset Management
Luxembourg
$2.39M +$4.13M +219,874 +898%
Morgan Stanley
31
Morgan Stanley
New York
$2.28M +$3.5M +186,189 +397%
Wellington Management Group
32
Wellington Management Group
Massachusetts
$2.2M +$465K +24,715 +12%
PPA
33
Parametric Portfolio Associates
Washington
$1.92M +$2.22M +117,807 +150%
LP
34
LMR Partners
United Kingdom
$1.92M +$2.73M +145,000 +282%
DA
35
Duality Advisers
Florida
$1.67M +$2.73M +145,306 +571%
SCM
36
Silverarc Capital Management
Massachusetts
$1.57M +$2.32M +123,277 +331%
Two Sigma Investments
37
Two Sigma Investments
New York
$1.49M +$2.87M +152,649 New
CSS
38
Cubist Systematic Strategies
Connecticut
$1.49M +$2.39M +127,176 +512%
OQS
39
Occudo Quantitative Strategies
Florida
$1.44M +$2.77M +147,559 New
Barclays
40
Barclays
United Kingdom
$1.37M +$1.44M +76,704 +121%
D.E. Shaw & Co
41
D.E. Shaw & Co
New York
$1.37M +$2.63M +139,908 New
Bank of New York Mellon
42
Bank of New York Mellon
New York
$1.34M -$559K -29,750 -18%
Jane Street
43
Jane Street
New York
$1.34M +$2.13M +113,310 +477%
JP Morgan Chase
44
JP Morgan Chase
New York
$1.21M +$1.83M +97,250 +364%
Walleye Capital
45
Walleye Capital
New York
$1.13M +$2.06M +109,674 +1,862%
PVI
46
Pura Vida Investments
New York
$1.12M +$1.22M +64,945 +130%
AG
47
Artal Group
Luxembourg
$977K
SA
48
Sunesis Advisors
Kansas
$941K
Swiss National Bank
49
Swiss National Bank
Switzerland
$875K
HWAM
50
Hennion & Walsh Asset Management
New Jersey
$866K +$359K +19,087 +27%

DCPH Hedge Fund Activity: Q4 2021 in Review

140 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q4 2021, worth a combined $450M — down 69% from $1.43B a quarter earlier.

Sellers outnumbered buyers: 49 funds closed out of DCPH and 29 opened new positions — a net loss of 20 holders — while 32 trimmed existing stakes and 58 added.

The largest buyer was Deerfield Management, adding an estimated $89.6M. The largest seller was Franklin Resources, exiting entirely with an estimated $109M sold.

  • 140 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q4 2021, down from 161 in Q3 2021.
  • Funds reported $450M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q4 2021, down 69% quarter-over-quarter.
  • 29 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q4 2021 and 49 closed out, a net change of -20 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q4 2021 was Deerfield Management, an estimated $89.6M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q4 2021 was Franklin Resources, an estimated $109M sold.

Based on aggregated 13F filings for Q4 2021.